CRNX insider transaction filings
Crinetics Pharmaceuticals, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-11. Screen CRNX transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-11 | 4 | Struthers Richard Scott — President & CEO, Director | Option exercise (M): 3,969 @ $25.19 · Option exercise (M): 4,422 @ $22.61 · Option exercise (M): 6,542 @ $15.29 · Option exercise (M): 4,995 @ $20.02 · Option exercise (M): 3,969 (derivative) @ $0 · Option exercise (M): 4,422 (derivative) @ $0 · +2 more | EDGAR |
| 2026-07-07 | 4 | Vivaldi Coelho Rogerio — Director | Sale (S): 3,000 @ $40 | EDGAR |
| 2026-06-22 | 4 | Deardorf Caren — Director | Grant/award (A): 5,925 @ $0 · Grant/award (A): 9,730 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Nichols Weston — Director | Grant/award (A): 5,925 @ $0 · Grant/award (A): 9,730 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Okey Stephanie — Director | Grant/award (A): 5,925 @ $0 · Grant/award (A): 9,730 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Vivaldi Coelho Rogerio — Director | Grant/award (A): 5,925 @ $0 · Grant/award (A): 9,730 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Fust Matthew K — Director | Grant/award (A): 5,925 @ $0 · Grant/award (A): 9,730 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Bedrosian Camille L — Director | Grant/award (A): 5,925 @ $0 · Grant/award (A): 9,730 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | WIERENGA WENDELL — Director | Grant/award (A): 5,925 @ $0 · Grant/award (A): 9,730 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Okey Stephanie — Director | Sale (S): 6,292 @ $35.62 · Sale (S): 608 @ $36.22 | EDGAR |
| 2026-06-02 | 4 | Struthers Richard Scott — President & CEO, Director | Gift (G): 222,200 @ $0 · Gift (G): 222,200 @ $0 · Gift (G): 80,000 @ $0 · Gift (G): 222,200 @ $0 · Gift (G): 222,200 @ $0 · Gift (G): 80,000 @ $0 · +8 more | EDGAR |
| 2026-04-10 | 4 | Knight Jeff E. — Chief Dev. & Operating Officer | Option exercise (M): 49,474 @ $23.98 · Option exercise (M): 9,624 @ $20.02 · Option exercise (M): 19,336 @ $19.64 · Sale (S): 85,163 @ $40.10 · Option exercise (M): 49,474 (derivative) @ $0 · Option exercise (M): 9,624 (derivative) @ $0 · +1 more | EDGAR |
| 2026-03-18 | 4 | Knight Jeff E. — Chief Operating Officer | Sale (S): 5,950 @ $37.11 · Sale (S): 3,961 @ $37.77 | EDGAR |
| 2026-03-18 | 4 | Betz Stephen F. — Chief Scientific Officer | Sale (S): 6,371 @ $37.11 · Sale (S): 4,241 @ $37.77 | EDGAR |
| 2026-03-18 | 4 | Struthers Richard Scott — President & CEO, Director | Sale (S): 13,196 @ $37.11 · Sale (S): 8,785 @ $37.77 | EDGAR |
| 2026-03-13 | 4 | Vivaldi Coelho Rogerio — Director | Sale (S): 4,477 @ $36.08 · Sale (S): 523 @ $36.77 | EDGAR |
| 2026-03-04 | 4 | Okey Stephanie — Director | Sale (S): 3,000 @ $39.67 | EDGAR |
| 2026-03-04 | 4 | Schilke Tobin — Chief Financial Officer | Sale (S): 6,713 @ $39.67 | EDGAR |
| 2026-02-25 | 4 | Struthers Richard Scott — President & CEO, Director | Grant/award (A): 62,000 @ $0 · Grant/award (A): 228,000 (derivative) @ $0 | EDGAR |
| 2026-02-25 | 4 | Schilke Tobin — Chief Financial Officer | Grant/award (A): 32,000 @ $0 · Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-02-25 | 4 | Knight Jeff E. — Chief Operating Officer | Grant/award (A): 34,000 @ $0 · Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2026-02-25 | 4 | Betz Stephen F. — Chief Scientific Officer | Grant/award (A): 30,000 @ $0 · Grant/award (A): 47,000 (derivative) @ $0 | EDGAR |
| 2026-02-25 | 4 | Kalofonos Isabel — Chief Commercial Officer | Grant/award (A): 34,000 @ $0 · Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2026-01-07 | 4 | Kalofonos Isabel — Chief Commercial Officer | Option exercise (M): 2,500 @ $40.59 · Sale (S): 2,500 @ $55 · Option exercise (M): 2,500 (derivative) @ $0 | EDGAR |
| 2025-12-29 | 4 | Betz Stephen F. — Chief Scientific Officer | Option exercise (M): 18,000 @ $1.91 · Option exercise (M): 18,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | Struthers Richard Scott — President & CEO, Director | Option exercise (M): 16,342 @ $9.28 · Option exercise (M): 28,400 @ $15.29 · Option exercise (M): 16,342 (derivative) @ $0 · Option exercise (M): 28,400 (derivative) @ $0 | EDGAR |
| 2025-12-03 | 4 | Pizzuti Dana — Chief Med and Dev Officer | Option exercise (M): 5,000 @ $16.89 · Sale (S): 5,000 @ $45.02 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2025-11-05 | 4 | Pizzuti Dana — Chief Med and Dev Officer | Option exercise (M): 5,000 @ $16.89 · Sale (S): 4,900 @ $42.65 · Sale (S): 100 @ $43.27 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2025-10-03 | 4 | Pizzuti Dana — Chief Med and Dev Officer | Option exercise (M): 5,000 @ $16.89 · Sale (S): 5,000 @ $41.81 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2025-09-30 | 4 | Struthers Richard Scott — President & CEO, Director | Sale (S): 4,000 @ $45 | EDGAR |
| 2025-09-30 | 4 | Fust Matthew K — Director | Option exercise (M): 10,000 @ $1.91 · Sale (S): 16,000 @ $44.75 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2025-09-04 | 4 | Pizzuti Dana — Chief Med and Dev Officer | Option exercise (M): 5,000 @ $16.89 · Sale (S): 5,000 @ $32.10 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2025-08-26 | 4 | Pizzuti Dana — Chief Med and Dev Officer | Option exercise (M): 30,000 @ $16.89 · Sale (S): 30,000 @ $30.43 · Option exercise (M): 30,000 (derivative) @ $0 | EDGAR |
| 2025-08-21 | 4 | Pizzuti Dana — Chief Med and Dev Officer | Sale (S): 6,492 @ $29.18 | EDGAR |
| 2025-06-16 | 4 | Betz Stephen F. — Chief Scientific Officer | Option exercise (M): 71,525 @ $1.91 · Option exercise (M): 16,645 @ $9.28 · Sale (S): 97,483 @ $32.23 · Option exercise (M): 71,525 (derivative) @ $0 · Option exercise (M): 16,645 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Okey Stephanie — Director | Grant/award (A): 6,900 @ $0 · Grant/award (A): 10,350 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Deardorf Caren — Director | Grant/award (A): 6,900 @ $0 · Grant/award (A): 10,350 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Nichols Weston — Director | Grant/award (A): 6,900 @ $0 · Grant/award (A): 10,350 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Vivaldi Coelho Rogerio — Director | Grant/award (A): 6,900 @ $0 · Grant/award (A): 10,350 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Fust Matthew K — Director | Grant/award (A): 6,900 @ $0 · Grant/award (A): 10,350 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Bedrosian Camille L — Director | Grant/award (A): 6,900 @ $0 · Grant/award (A): 10,350 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | WIERENGA WENDALL — Director | Grant/award (A): 6,900 @ $0 · Grant/award (A): 10,350 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | Struthers Richard Scott — President & CEO, Director | Gift (G): 90,400 @ $0 · Gift (G): 90,400 @ $0 | EDGAR |
| 2025-04-04 | 4 | Struthers Richard Scott — President & CEO, Director | Option exercise (M): 81,270 @ $1.91 · Option exercise (M): 81,270 (derivative) @ $0 | EDGAR |
| 2025-03-21 | 4 | Pizzuti Dana — Chief Med and Dev Officer | Sale (S): 2,388 @ $34.17 · Sale (S): 127 @ $34.83 | EDGAR |
| 2025-03-21 | 4 | Knight Jeff E. — Chief Operating Officer | Sale (S): 6,801 @ $34.17 · Sale (S): 361 @ $34.83 | EDGAR |
| 2025-03-21 | 4 | Betz Stephen F. — Chief Scientific Officer | Sale (S): 5,479 @ $34.17 · Sale (S): 291 @ $34.83 | EDGAR |
| 2025-03-21 | 4 | Struthers Richard Scott — President & CEO, Director | Sale (S): 16,463 @ $34.17 · Sale (S): 875 @ $34.83 | EDGAR |
| 2025-03-11 | 4 | Schilke Tobin — Chief Financial Officer | Grant/award (A): 52,000 @ $0 · Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2025-02-24 | 4 | Struthers Richard Scott — President & CEO, Director | Grant/award (A): 89,000 @ $0 · Grant/award (A): 313,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Crinetics Pharmaceuticals, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-19 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-08-14 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-08-03 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-10 | 8-K | 1.01 — Entry into a Material Definitive Agreement 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-07-06 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-22 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-10 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-23 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-03-03 | 8-K | 4.01 — Changes in Registrant's Certifying Accountant 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CRNX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →